

# *VIRTUAL* 2021 Bon Secours Cancer Institute Summit

September 17, 2021—8am to 4:30pm

Watch this event remotely:

[https://bsmh.zoom.us/webinar/register/WN\\_-\\_ak\\_VtSSeGIL-AasQTe6Q](https://bsmh.zoom.us/webinar/register/WN_-_ak_VtSSeGIL-AasQTe6Q)

Register for this event:

[www.eeds.com/live/666675](http://www.eeds.com/live/666675)



# PROGRAM DESCRIPTION

Cancer treatment guidelines change rapidly; common treatment one year ago is no longer standard treatment today. Changes in guidelines are challenging to keep up with as physicians struggle with time constraints and patient load to have opportunities to discuss the latest updates. The standard of care for cancer treatment requires a multidisciplinary approach.

The 2021 Bon Secours Cancer Summit conference is a forum to bridge the gap between independent providers. At this summit, a review of updates to NCCN guidelines and changes to treatment recommendations are evaluated with 360-degree input so many can benefit from research and time spent by individual clinicians. Using a conference to review, evaluate and apply new technology and research results using a multidisciplinary approach allows for adherence to guidelines and ensures patients receive timely treatment resulting in improved quality of care. The mission to provide Good Help to Those in Need® takes on special meaning in the care

of our cancer patients and their families. We strive to provide an environment where healing and hope can flourish.

At the Bon Secours Cancer Institute, our expert care team members combine science with the art of compassion. World-class surgical, medical and radiation oncology experts; certified oncology nurses; and support staff collaborate to offer the latest and most effective inpatient and outpatient cancer treatments.

For the 2021 Bon Secours Cancer Summit, we have chosen the following topics due to the timeliness with what the public is seeing in the media and the need for primary care and oncology physicians to have the ability to speak with their patients and answer questions on these topics and to address gaps in the literature: **Cancer Prevention and Screening Post-Pandemic, Physician Patient Communication, Post-Treatment Sexual Health, Endocrine Therapy Compliance, Genomic Factors to Optimize Systemic Therapy for High Risk Prostate Cancer and Precision Medicine.**

**TARGET AUDIENCE:** Primary care physicians, specialists, surgeons, medical oncologists, radiation oncologists, nurse practitioners and other healthcare professionals interested in a deeper knowledge and understanding of the full continuum of cancer care including healthy survivorship.

**LEARNING OBJECTIVES:** At the conclusion of this activity, participants should be able to:

- Highlight the importance of multi-disciplinary team approach using common verbiage when communicating course of treatment with the oncology patient.
- Elaborate on the future precision medicine when discussing treatment management of oncology patients.
- Describe the importance of having open sexual health conversations with oncology patients.
- Delineate best practices concerning the application of targeted therapies in frontline and subsequent setting in the treatment of high risk prostate malignancies.
- Apply current consensus guidelines, advances, and best practices when ordering screening studies post pandemic.

**REGISTRATION:** Registration is free and available online at [www.eeds.com/live/666675](http://www.eeds.com/live/666675). Visit the website and click on “Register Now.” Registration deadline is September 9.

# AGENDA

Friday, September 17, 2021

<b>8-8:15am</b>	Welcome Address and Invocation	<b>William Irvin, Jr., MD</b> Medical Director for Oncology and Clinical Research Bon Secours Cancer Institute
<b>8:15-9:15am</b>	<i>The National Cancer Institute: Leading Cancer Research in 2021 and Beyond</i>	<b>Norman Sharpless, MD</b> Director, National Cancer Institute (NCI)
<b>9:15-10:15am</b>	<i>Words Matter: The Language of Respect</i>	<b>Tatiana Prowell, MD</b> Associate Professor of Oncology Breast Cancer Program Johns Hopkins Kimmel Comprehensive Cancer Center
<b>10:15-10:30am</b>	<b>Morning Break</b>	
<b>10:30-11:30am</b>	<i>Sexual Health</i>	<b>Jennifer Gass, MD</b> Chief of Surgery, Director, Breast Disease Fellowship Program Co-Director, Breast Health Center, Women & Infants Hospital, Providence, Rhode Island
<b>11:30am-12:30pm</b>	<i>Novel Evaluation of Patient Adherence to Endocrine Therapy</i>	<b>Stephanie Wheeler, PhD</b> Professor, Health Policy and Management, University of North Carolina Gillings School of Public Health Associate Director, Community Outreach and Engagement (COE), UNC Lineberger Comprehensive Cancer Center
<b>12:30-1pm</b>	<b>Lunch</b>	
<b>1-2pm</b>	<i>Using Genomic Factors to Optimize Systemic Therapy for High Risk Prostate Cancer</i>	<b>Paul Nguyen, MD</b> Professor of Radiation Oncology, Harvard Medical School Baldwin-Politi Family Distinguished Chair in Oncology, Vice-Chair for Clinical Research Dana-Farber/Brigham and Women's Cancer Center
<b>2-2:15pm</b>	<b>Afternoon Break</b>	
<b>2:15-3:15pm</b>	<i>Moving Precision Medicine into Routine Management of Cancer Patients</i>	<b>Howard McLeod, PharmD</b> Medical Director, Precision Medicine at the Geriatric Oncology Consortium Professor of Medicine and Pharmacy, University of South Florida
<b>3:15-4:15pm</b>	<i>The Caretaker Experience</i>	<b>Heart Works Panel</b> <i>Panelists:</i> Susan Moran and Megan McDowell
<b>4:15-4:30pm</b>	<i>"All Hope Awards"</i>  Alfred H. Rogers Courage Award	<b>Ryan Stuhldreier</b> Vice President, Service Line Strategy  <b>William Irvin, Jr., MD</b> Medical Director for Oncology and Clinical Research Bon Secours Cancer Institute



**Jennifer S. Gass, MD** is chief of surgery at Women & Infants Hospital, director of the Breast Fellowship at the Breast Health Center, as well as clinical assistant professor at Brown Medical School since 1993. She is board certified in both general surgery and critical care.

Dr. Gass received her medical degree (honors) from the University of Maryland Medical School, Baltimore, Maryland, and completed her internship and residency at Temple University Hospital. She was an assistant professor at Wayne State University from 1992 to 1993. She has full privileges at Women & Infants Hospital, Rhode Island Hospital, and Miriam Hospital. She was a member of the Breast Cancer Task Force of the Harvard Pilgrim Health Care Committee from 1995-1997.

Dr. Gass attended in the Surgical Intensive Care Unit at Rhode Island Hospital from 2002 to 2003. She is a member of the American Society of Breast Surgeons, Rhode Island Medical Women's Association, Rhode Island Medical Society, American Medical Women's Association, Association of Women Surgeons, American College of Surgeons, and American Medical Association.

Dr. Gass participates with Dr. Legare and Jennifer Scalia-Wilbur in the Cancer Risk Assessment and Prevention Program. Through Dr. Gass, the Breast Health Center has been chosen as a site for the multi-institutional Cryo-assisted Lumpectomy Trial. Dr. Gass currently offers cryoablation of fibroadenomas.



**Paul Nguyen, MD** is an expert in prostate cancer clinical care and research. He has published over three hundred original research articles and serves as the vice-chair of the ARS/ACR Appropriateness Criteria Committee for Prostate Cancer and was chair of the program

committee for the 2019 ASTRO/SUO/ASCO Genitourinary Cancers Symposium. He is the principal investigator of the multi-center randomized FORMULA-509 trial and co-chair of the international randomized ENZARAD trial. His research on biomarkers to personalize the use of androgen deprivation therapy is supported by an NIH R-01 award. He serves as the DF/BWCC Genitourinary Clinical Center Director for Radiation Oncology, Vice-Chair for Clinical Research in the

Department of Radiation Oncology, and professor at Harvard Medical School. He received his AB from Harvard College, MD from Harvard Medical School, and completed his residency at the Harvard Radiation Oncology Program where he served as chief resident.



**Howard McLeod, PharmD** is an internationally recognized expert in precision medicine, having made novel contributions at the discovery, translation, implementation, and policy levels. He is the Medical Director for Precision Medicine at the Geriatric Oncology Consortium

and a professor of medicine and pharmacy at the University of South Florida. Dr. McLeod chaired the NHGRI eMERGE network external scientific panel for the past decade and was a recent member of both the FDA committee on clinical pharmacology and the NIH Human Genome Advisory Council. Dr. McLeod has been recognized as a fellow of both the American Society of Clinical Oncology and the American College of Clinical Pharmacy and was recently ranked #1 USA/#2 world for pharmacogenomics. He has published over 580 peer-reviewed papers on pharmacogenomics, applied therapeutics, or clinical pharmacology and continues to work to advance innovative healthcare.



**Tatiana Prowell, MD** is Associate Professor of Oncology in the Breast Cancer Program at the Johns Hopkins Kimmel Comprehensive Cancer Center and Breast Cancer Scientific Liaison at the US Food & Drug Administration. She is a frequent public speaker and a passionate

medical educator, clinician, and mentor. She was a member of the Biden Cancer Moonshot Blue Ribbon Panel Cancer Immunology Working Group and was Chair of the 2020 ASCO Annual Meeting Education Committee. She has received the ASCO/AACR Merrill Egorin Mentorship Award, the John and Samuel Bard Medal in Science or Medicine, a Webby Special Achievement Award for use of social media during the COVID-19 pandemic, and is a two-time recipient of FDA's Excellence in Communication Award. Dr. Prowell received her BA degree from Bard College in languages and literature and completed medical school, internal medicine residency, and medical oncology fellowship training at Johns Hopkins with election

to the Phi Beta Kappa & Alpha Omega Alpha honor societies. She lives with her husband, three children, and one rescue dog in Maryland.



**Norman E. "Ned" Sharpless, MD** was officially sworn in as the fifteenth director of the National Cancer Institute (NCI) on October 17, 2017. Prior to his appointment, Dr. Sharpless served as the director of the Lineberger Comprehensive Cancer Center at the University of North Carolina

(UNC).

Dr. Sharpless was a Morehead Scholar at UNC-Chapel Hill and received his undergraduate degree in mathematics. He went on to pursue his medical degree from the UNC School of Medicine, graduating with honors and distinction in 1993. He then completed his internal medicine residency at the Massachusetts General Hospital and a hematology/oncology fellowship at Dana-Farber/Partners Cancer Care, both of Harvard Medical School in Boston. After 2 years on the faculty at Harvard Medical School, he joined the faculty of the UNC School of Medicine in the Departments of Medicine and Genetics in 2002. He became the Wellcome Professor of Cancer Research at UNC in 2012.

Dr. Sharpless is a member of the Association of American Physicians and the American Society for Clinical Investigation, and is a Fellow of the Academy of the American Association of Cancer Research. He has authored more than 160 original scientific papers, reviews, and book chapters and is an inventor on ten patents. He cofounded two clinical-stage biotechnology companies: G1 Therapeutics and Sapere Bio (formerly HealthSpan Diagnostics). He served as Acting Commissioner for Food and Drugs at the US FDA for seven months in 2019 before returning to the NCI Directorship.




**Stephanie Wheeler, PhD, MPH** is a professor of health policy and management at the University of North Carolina Gillings School of Public Health. As a health services researcher and decision scientist, her research is focused on understanding cancer care quality, access, equity, and value. Strong

and noteworthy aspects of her research portfolio are: leading studies focused on comparative and cost-effectiveness of breast cancer care; exploring patient preferences and values in medical

decision making; studying breast cancer health disparities and solutions; compiling and linking 'big data' from various sources to enable a more complete understanding of complex healthcare issues; and employing simulation tools to study important questions that traditional experimental or observational methods cannot feasibly address. Her work has been funded by more than \$20 million in research grants, including multiple investigator-initiated awards for which she serves as PI/MPI. Many of these grants have focused on understanding patterns of breast cancer care (American Cancer Society, PI: Wheeler), understanding financial impact of breast cancer among survivors (National Comprehensive Cancer Network/Pfizer, PI: Wheeler & Rosenstein), and describing the cost and cost-effectiveness of various cancer interventions (CDC, PI: Wheeler).

Dr. Wheeler currently leads the Coordinating Center of the CDC- and NCI-funded Cancer Prevention-funded Special Interest Project (SIP) Cancer Prevention and Control Research Network (CPCRN), a hallmark thematic research network of the CDC's Prevention Research Centers (PRC) Program. She also co-leads the NCI-funded T32 Cancer Care Quality Training Program at UNC, and the CDC- and NCI-funded Geographic Management of Cancer Health Disparities Program (GMaP) Region 1 South hub. In addition, she has co-led two other SIPs focused on the behavioral economics of cancer care (11-041, MPIs Wheeler and Pignone) and on the cost and cost-effectiveness of metastatic breast cancer treatments (17-004, MPIs Trogdon and Wheeler). Most recently, she has been appointed Associate Director of Community Outreach and Engagement (COE) for the UNC Lineberger Comprehensive Cancer Center, a role that involves leading and supporting research, clinical care, and programmatic efforts to: understand the cancer-specific needs of our catchment area, investigate and implement evidence-based strategies to promote cancer equity, engage the broader community in optimizing cancer outcomes, and coordinate, track and disseminate the products of COE efforts.



## COURSE DIRECTOR & PLANNING COMMITTEE

### **William Irvin, Jr, MD (Director)**

Medical Director for Oncology and Clinical Research  
Bon Secours Cancer Institute

### **James Pellicane, MD, FACS**

Breast Surgeon, Virginia Breast Center  
Medical Director, Breast Oncology, Bon Secours VA

### **Beth Brew, BSRT (R),(T), MBA**

Administrative Director, Oncology Services  
Bon Secours Richmond

### **Michael White, MD, FACS, MS**

Surgical Oncologist, Bon Secours St. Mary's Hospital

### **Marylou Anton, MSN, RN, OCN**

Administrative Director, Oncology Services  
Bon Secours Hampton Roads

### **Ryan Stuhldreier, BS, MBA**

VP Service Line Strategy,  
Bon Secours Richmond

### **George Parker, MD, FACS**

General Surgeon  
Bon Secours St. Mary's Hospital

### **Lang R. Liebman, MD**

Radiation Oncology Medical Director  
Bon Secours Cancer Institute Richmond

### **Tracey Tatum, NP**

Manager, Oncology Navigation and Genetic Program  
Bon Secours Richmond

## VISITING FACULTY

### **Jennifer Gass, MD**

Chief of Surgery, Director, Breast Disease Fellowship  
Program; Co-Director, Breast Health Center,  
Women & Infants Hospital, Providence, Rhode Island

### **Howard McLeod, PharmD**

Medical Director, Precision Medicine,  
Geriatric Oncology Consortium  
Professor of Medicine and Pharmacy,  
University of South Florida

### **Paul Nguyen, MD**

Professor of Radiation Oncology, Harvard Medical  
School Baldwin-Politi Family Distinguished Chair in  
Oncology Vice-Chair for Clinical Research  
Dana-Farber/Brigham and Women's Cancer Center

### **Tatiana Prowell, MD**

Associate Professor of Oncology  
Breast Cancer Program  
Johns Hopkins Kimmel Comprehensive  
Cancer Center

### **Norman Sharpless, MD**

Director, National Cancer Institute (NCI)

### **Stephanie Wheeler, PhD**

Professor, Health Policy and Management,  
University of North Carolina  
Gillings School of Public Health  
Associate Director, Community Outreach and  
Engagement (COE), UNC Lineberger  
Comprehensive Cancer Center

## Accreditation and Designation Statement

In support of improving patient care, this activity has been planned and implemented by Bon Secours Richmond Health System and Mercy Health St. Rita's Medical Center. Mercy Health St. Rita's Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

## Credit Designation

- Mercy Health St. Rita's Medical Center designates this live activity for a maximum of 7 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- Mercy Health St. Rita's Medical Center designates this live activity for a maximum of 7 Hour(s) Attendance w/ No Credit.
- Mercy Health St. Rita's Medical Center designates this live activity for a maximum of 7 Hour(s) NCPD (ANCC Contact Hours).
- Mercy Health St. Rita's Medical Center designates this live activity for a maximum of 7 Hour(s) ACPE.
- Mercy Health St. Rita's Medical Center designates this live activity for a maximum of 7 Credit(s) IPCE.

## Event Disclosures

### **Speakers:**

**Howard McLeod, PharmD** has disclosed a financial relationship with an ineligible company in the last 24 months:

- Vyant Bio - Board Member - Relationship Has Not Ended
- Viecure - Advisory Committee Member - Relationship Has Not Ended
- Clariifi LLC - Co-Founder - Relationship Has Not Ended
- EviCORE - Advisory Committee Member - Relationship Has Not Ended

**Paul Nguyen, MD** has disclosed a financial relationship with an ineligible company in the last 24 months:

- Janssen - Contracted Research - Relationship Has Not Ended
- Astellas - Contracted Research - Relationship Has Not Ended
- Bayer - Contracted Research - Relationship Has Not Ended
- Boston Scientific - Consulting - Relationship Has Not Ended
- Myovant - Consulting - Relationship Has Not Ended

**Stephanie Wheeler, PhD** has disclosed a financial relationship with an ineligible company in the last 24 months:

- Pfizer Medical Foundation - Contracted Research - Relationship Has Not Ended

**Jennifer Gass, MD, Tatiana Prowell, MD, Norman Sharpless, MD, Susan Moran, and Megan McDowell** have no financial relationships to report in the last 24 months with an ineligible company.

### **Planners and other Administrative Support:**

**James Pellicane, MD** has disclosed a financial relationship with an ineligible company in the last 24 months:

- Agendia - Speakers Bureau - Relationship Has Not Ended
- Prelude Dx - Speakers Bureau - Relationship Has Not Ended

**Beth Brew, MBA; William Irvin, Jr., MD; Marylou Anton, RN; Tracey Tatum, NP; Ryan Stuhldreier, MBA; Michael White, MD; Lang Liebman, MD; and George Parker, MD** have no financial relationships to report in the last 24 months with an ineligible company.

## Commercial Support:

This activity is not commercially supported.



5875 Bremond Rd, Suite 108  
Richmond, VA 23226